Company: RGBP
Filing Date: 2025-05-16
Form Type: 10-Q
Source: 0001641172-25-011206
Chunk: 5

Company: Regen BioPharma Inc
Filing Date: 2025-05-16
Form: 10-Q
Item: Part I, Item 1
Chunk 5
---
Related Party)                                $17,733  
 ────────────────────────────────────────────────────────────────────────────────

L. STOCK-BASED COMPENSATION

The Company accounts for
share-based compensation in accordance with the fair value recognition provisions of FASB ASC Topic 718, Share-based Payment, which requires
all share-based payments to employees, including grants of employee stock options, to be recognized in the consolidated financial statements
based on their fair values. The fair value of stock options is calculated by using the Black-Scholes option pricing formula that requires
estimates for expected volatility, expected dividends, the risk-free interest rate and the term of the option. If any of the assumptions
used in the Black-Scholes model change significantly, share-based compensation expense may differ materially in the future from that recorded
in the current period.

M. SEGMENT REPORTING

FASB ASC Topic 280, Segment
Reporting, requires public companies to report financial and descriptive information about their reportable operating segments. The Company’s
management identifies operating segments based on how the Company’s management internally evaluate separate financial information,
business activities and management responsibility. At the current time, the Company has only one reportable segment, primarily in the
development of regenerative medical applications

N. INCOME TAXES

The Company uses the asset
and liability method of accounting for income taxes in accordance with ASU 740, “ Income Taxes”. Under this method, income
tax expense is recognized as the amount of: (i) taxes payable or refundable for the current year and (ii) future tax consequences attributable
to differences between the consolidated financial statements carrying amounts of existing assets and liabilities and their respective
tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years which
those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in
tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided
to reduce the deferred tax assets reported if based on the weight of available evidence it is more likely than not that some portion or
all of the deferred tax assets will not be realized. The Company is subject to Income tax filings requirements in U. S. federal and various
state jurisdictions. The Company’s tax returns for all years are subject to U. S. federal, state, and local income tax examinations
by tax authorities. The Company reports income tax